ANI PHARMACEUTICALS, INC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M | $208.5M | $206.5M | $201.6M |
| Cost of Revenue | — | — | — | — | — | $87.2M | $63.2M | $73.0M |
| Gross Profit | — | — | — | — | — | $121.3M | $143.4M | $128.6M |
| Gross Margin | — | — | — | — | — | 58.2% | 69.4% | 63.8% |
| Operating Expenses | ||||||||
| Research & Development | $51.7M | $44.6M | $34.3M | $22.3M | $11.4M | $16.0M | $19.8M | $15.4M |
| SG&A Expense | $317.7M | $249.6M | $161.7M | $124.0M | $84.3M | $65.0M | $55.8M | $44.1M |
| Operating Income | $111.1M | $584.0K | $47.0M | $-35.3M | $-39.8M | $-16.0M | $16.4M | $35.4M |
| Operating Margin | 12.6% | 0.1% | 9.6% | -11.2% | -18.4% | -7.7% | 7.9% | 17.5% |
| Interest Expense | $32.6M | $33.6M | $35.6M | $28.5M | $11.9M | $9.5M | $13.5M | $14.9M |
| Pretax Income | $95.8M | $-22.2M | $19.9M | $-62.7M | $-56.1M | $-26.0M | $3.2M | $20.1M |
| Income Tax Expense | $17.5M | $-3.7M | $1.1M | $-14.8M | $-13.5M | $-3.4M | $-2.9M | $4.6M |
| Net Income | $78.3M | $-18.5M | $18.8M | $-47.9M | $-42.6M | $-22.5M | $6.1M | $15.5M |
| Net Margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 3.0% | 7.7% |
| EPS (Basic) | $3.50 | $-1.04 | $0.86 | $-3.05 | $-3.40 | $-1.88 | $0.51 | $1.31 |
| EPS (Diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 |
| Shares Outstanding (Basic) | 20.1M | 19.3M | 18.0M | 16.3M | 12.6M | 12.0M | 11.8M | 11.7M |
| Shares Outstanding (Diluted) | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M | 12.0M | 12.0M | 11.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |